Alar (artemether + lumefantrine): Uses, Dosage & Side Effects

What it's for (Indications)

Artemether + lumefantrine is indicated for the treatment of uncomplicated *Plasmodium falciparum* malaria in adults and children weighing 5 kg and above.
This includes infections acquired in geographical areas where chloroquine resistance or resistance to other antimalarials is prevalent, making it a crucial first-line therapy in many endemic regions.
It is essential to emphasize that this therapy is specifically designed for uncomplicated malaria, meaning cases that do not present with severe manifestations such as cerebral malaria, severe anemia, acute renal failure, pulmonary edema, or other signs of severity.
The oral formulation is not appropriate for severe malaria, which requires parenteral treatment.
While artemether possesses activity against *P.
vivax*, *P.
ovale*, or *P.
malariae* infections, the efficacy of artemether + lumefantrine against these species has not been comprehensively established through systematic clinical trials, and it is primarily used for *P.
falciparum* infections.
Before prescribing, confirmation of *P.
falciparum* infection is recommended, though treatment may be initiated based on clinical suspicion in areas with high transmission rates where prompt treatment is vital.
This medication is a cornerstone in the global effort to combat drug-resistant *P.
falciparum* malaria.

Dosage Information

Type	Guideline
Standard	Artemether + lumefantrine is administered orally as a 6-dose regimen over 3 days. For adults and children weighing 35 kg and above, the recommended dosage involves an initial dose of four tablets (each containing 20 mg artemether and 120 mg lumefantrine), followed by five additional doses of four tablets each at 8, 24, 36, 48, and 60 hours after the initial dose. For pediatric patients weighing 5 kg to less than 35 kg, the dosage is strictly weight-dependent and must be carefully prescribed by a healthcare professional, typically involving a lower number of tablets per dose to ensure appropriate drug exposure. A critical aspect of administration is that each dose must be taken with food or a fatty meal (e.g., milk, peanut butter) to ensure adequate absorption of both components, particularly lumefantrine, which is highly lipophilic. Inadequate absorption significantly reduces efficacy and can lead to treatment failure or recrudescence. If a patient vomits within 1 hour of taking any dose, a full repeat dose should be administered. Patients must be strongly advised to complete the entire 3-day, 6-dose course of therapy, even if symptoms improve, to maximize therapeutic efficacy and prevent potential recrudescence or the development of drug resistance. Adherence to the full regimen is paramount for successful treatment.

Type

Guideline

Standard

Artemether + lumefantrine is administered orally as a 6-dose regimen over 3 days. For adults and children weighing 35 kg and above, the recommended dosage involves an initial dose of four tablets (each containing 20 mg artemether and 120 mg lumefantrine), followed by five additional doses of four tablets each at 8, 24, 36, 48, and 60 hours after the initial dose. For pediatric patients weighing 5 kg to less than 35 kg, the dosage is strictly weight-dependent and must be carefully prescribed by a healthcare professional, typically involving a lower number of tablets per dose to ensure appropriate drug exposure. A critical aspect of administration is that each dose *must* be taken with food or a fatty meal (e.g., milk, peanut butter) to ensure adequate absorption of both components, particularly lumefantrine, which is highly lipophilic. Inadequate absorption significantly reduces efficacy and can lead to treatment failure or recrudescence. If a patient vomits within 1 hour of taking any dose, a full repeat dose should be administered. Patients must be strongly advised to complete the entire 3-day, 6-dose course of therapy, even if symptoms improve, to maximize therapeutic efficacy and prevent potential recrudescence or the development of drug resistance. Adherence to the full regimen is paramount for successful treatment.

Safety & Warnings

Common Side Effects

The most commonly reported side effects associated with artemether + lumefantrine are generally mild to moderate in intensity and transient.
These frequently include headache, dizziness, nausea, vomiting, abdominal pain, diarrhea, asthenia (generalized weakness or fatigue), anorexia (loss of appetite), arthralgia (joint pain), and myalgia (muscle pain).
Less common but potentially more serious adverse events include hypersensitivity reactions, which may manifest as skin rash, urticaria (hives), or, in rare instances, more severe systemic reactions.
Of particular clinical concern are the cardiac effects, specifically the potential for QT interval prolongation, which has been observed with this medication.
While usually modest, this prolongation warrants careful consideration, especially in patients with pre-existing cardiac conditions or those concomitantly receiving other QT-prolonging drugs.
Other reported adverse reactions include sleep disorders (insomnia or somnolence), palpitations, cough, pruritus (itching), and other dermatological reactions.
Patients should be cautioned that dizziness or somnolence may occur, potentially impairing their ability to drive or operate heavy machinery safely.
Any persistent, severe, or unusual side effects should be promptly reported to a healthcare professional for evaluation.

Serious Warnings

Black Box Warning: **Serious Warnings: Potential for Cardiac Arrhythmias and Critical Drug Interactions** While artemether + lumefantrine does not currently carry an FDA-mandated Black Box Warning, it is imperative for healthcare professionals and patients to be fully cognizant of several critical safety concerns that warrant prominent attention. This medication is known to cause dose- and concentration-dependent prolongation of the QT interval, which carries a significant risk of predisposing patients to serious, potentially life-threatening ventricular arrhythmias, including Torsade de Pointes. Therefore, a thorough cardiac history should be obtained for all patients, evaluating for pre-existing cardiac conditions such as a history of QT prolongation, cardiac arrhythmias, or a family history of congenital QT prolongation. Any uncorrected electrolyte imbalances, particularly hypokalemia or hypomagnesemia, must be corrected prior to initiating therapy, as these conditions significantly amplify the risk of cardiac arrhythmias. Concurrent administration with other medications known to prolong the QT interval is contraindicated due to additive effects on cardiac repolarization, which can precipitate dangerous arrhythmias. Similarly, caution is strongly advised regarding the co-administration with potent inducers or inhibitors of cytochrome P450 3A4 (CYP3A4), as these interactions can profoundly alter the drug's plasma concentrations. Potent CYP3A4 inhibitors can increase exposure to artemether and lumefantrine, elevating the risk of toxicity, including cardiac effects. Conversely, potent CYP3A4 inducers can decrease drug exposure, potentially leading to subtherapeutic levels and treatment failure. Patients must be strictly advised to take artemether + lumefantrine with food or a fatty meal to ensure adequate absorption and prevent suboptimal drug levels that could result in treatment failure or recrudescence. Patients should seek immediate medical attention if they experience symptoms suggestive of cardiac issues, such as palpitations, chest pain, dizziness, or syncope.
Artemether + lumefantrine should be used with extreme caution in patients with a known history of cardiac arrhythmias, significant bradycardia, or a family history of congenital QT prolongation, due to the inherent risk of QT interval prolongation.
This cardiac effect can potentially lead to serious ventricular arrhythmias, including the life-threatening Torsade de Pointes.
Prior to initiating therapy, it is advisable to assess for and correct any uncorrected electrolyte imbalances, such as hypokalemia or hypomagnesemia, which can further exacerbate QT prolongation.
Co-administration with other drugs known to prolong the QT interval (e.
g.
, certain antiarrhythmics, antipsychotics, antidepressants, macrolide antibiotics, fluoroquinolones, and specific antifungals) is contraindicated or necessitates stringent cardiac monitoring due to the additive risk.
Both artemether and lumefantrine are metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system.
Therefore, concurrent use with potent CYP3A4 inhibitors (e.
g.
, ketoconazole, ritonavir, grapefruit juice) or inducers (e.
g.
, rifampin, carbamazepine, St.
John's Wort) can significantly alter the plasma concentrations of artemether and lumefantrine, potentially compromising efficacy (with inducers) or increasing toxicity (with inhibitors).
Patients must be explicitly instructed to take each dose of artemether + lumefantrine with food or a fatty meal to ensure adequate absorption and achieve therapeutic drug levels; failure to do so can result in subtherapeutic levels and increase the risk of malaria recrudescence or treatment failure.
Furthermore, patients should be advised against using other antimalarial medications concurrently unless specifically indicated and under close medical supervision, as this may lead to additive toxicities or unpredictable pharmacokinetic interactions.

How it Works (Mechanism of Action)

Artemether and lumefantrine are a fixed-dose combination antimalarial therapy that exerts its effects through distinct yet complementary mechanisms, targeting the asexual erythrocytic stages of *Plasmodium falciparum*. Artemether, an artemisinin derivative, acts rapidly upon entering the parasite's food vacuole. Its endoperoxide bridge is cleaved by parasitic heme, generating highly reactive free radicals. These free radicals form covalent adducts with various parasite proteins, lipids, and other macromolecules, leading to widespread cellular damage, disruption of parasite membrane function, inhibition of protein synthesis, and ultimately, rapid parasite death. Lumefantrine, an aryl-amino alcohol, possesses a longer half-life and acts primarily by interfering with the detoxification of heme within the parasite. *P. falciparum* digests host hemoglobin, releasing toxic free heme. The parasite typically polymerizes this heme into a non-toxic crystalline substance called hemozoin. Lumefantrine inhibits this polymerization process, leading to an accumulation of toxic free heme, which damages parasitic membranes through lipid peroxidation and inhibits essential enzyme systems, thereby killing the parasite. The combination of artemether's rapid parasitic clearance and lumefantrine's sustained antimalarial effect provides a potent, synergistic action that swiftly reduces parasitic biomass, prevents recrudescence by clearing residual parasites, and is effective against multi-drug resistant strains of *P. falciparum*.